Affordable Access

deepdyve-link
Publisher Website

Bioequivalence evaluation of rilmenidine in healthy volunteers.

Authors
  • Groenewoud, Gerhard
  • Potgieter, Linda
  • Meyer, Bernhardt
Type
Published Article
Journal
Arzneimittel-Forschung
Publication Date
Jan 01, 2009
Volume
59
Issue
5
Pages
233–237
Identifiers
DOI: 10.1055/s-0031-1296390
PMID: 19537523
Source
Medline
License
Unknown

Abstract

The bioavailability of two rilmenidine tablet formulations was compared in healthy male (17) and female (8) subjects, aged 18 to 36 years, during a laboratory-blind, randomized, two-treatment, two-period, cross-over study under fasting conditions. In each treatment phase subjects received a single dose of 1.544 mg rilmenidine dihydrogen phosphate (CAS 85409-38-7), equivalent to 1 mg rilmenidine (CAS 54187-04-1). Consecutive dosing was separated by a drug-free wash-out period of 7 d. Following each dosing, serial venous blood samples were collected over a period of 48 h for the determination of plasma rilmenidine concentrations by means of a validated LCMS/MS method. The most frequently reported drug-related adverse events were dizziness and headache ranging from mild to moderate in intensity. The geometric mean C(max) of rilmenidine for the reference and test products was 3.73 and 3.97 ng/ml, respectively. The corresponding geometric mean AUC(0-infinity)) was 34.0 and 35.1 ng x h/ml. T(max) for both products under investigation appeared at 1.33 h. The test product was shown to be bioequivalent to the reference product with respect to all pharmacokinetic variables investigated.

Report this publication

Statistics

Seen <100 times